Then, we also observed its high expression in several BM samples from APL and CML patients, some of which were negative for WT1, suggesting that using both antigens as CTL epitopes would broaden the number of patients who can receive immunotherapy. Here, WT1 is linked to acute promyelocytic leukemia.